Total Payments
$10,680
2024 Payments
$23.93
Companies
10
Transactions
25
Medicare Patients
226
Medicare Billing
$38,090
Payment Breakdown by Category
Research$8,038 (75.3%)
Other$1,855 (17.4%)
Food & Beverage$747.95 (7.0%)
Education$38.84 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8,038 | 7 | 75.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,855 | 2 | 17.4% |
| Food and Beverage | $747.95 | 13 | 7.0% |
| Education | $38.84 | 3 | 0.4% |
Payments by Type
Research
$8,038
7 transactions
General
$2,642
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $6,970 | 5 | $0 (2023) |
| F. Hoffmann-La Roche AG | $2,159 | 3 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $995.07 | 4 | $0 (2019) |
| Gilead Sciences, Inc. | $169.44 | 4 | $0 (2024) |
| Daiichi Sankyo Inc. | $156.68 | 2 | $0 (2022) |
| EMD Serono Research & Development Institute | $88.19 | 1 | $0 (2017) |
| PFIZER INC. | $56.44 | 3 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $50.73 | 1 | $0 (2017) |
| BeiGene USA, Inc. | $19.28 | 1 | $0 (2022) |
| Helsinn Therapeutics (U.S.), Inc. | $14.96 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23.93 | 1 | Gilead Sciences, Inc. ($23.93) |
| 2023 | $433.59 | 3 | Eli Lilly and Company ($300.00) |
| 2022 | $1,076 | 4 | Eli Lilly and Company ($900.00) |
| 2021 | $640.82 | 3 | Eli Lilly and Company ($325.00) |
| 2020 | $300.00 | 1 | Eli Lilly and Company ($300.00) |
| 2019 | $7,095 | 7 | Eli Lilly and Company ($5,145) |
| 2018 | $96.24 | 2 | Novartis Pharmaceuticals Corporation ($92.67) |
| 2017 | $1,014 | 4 | Novartis Pharmaceuticals Corporation ($875.06) |
All Payment Transactions
25 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/10/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $23.93 | General |
| Category: ONC | ||||||
| 12/15/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $98.97 | General |
| 09/27/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $34.62 | General |
| 04/28/2023 | Eli Lilly and Company | — | — | In-kind items and services | $300.00 | Research |
| Study: A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+ HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | ||||||
| 12/05/2022 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: Oncology | ||||||
| 11/29/2022 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Food and Beverage | In-kind items and services | $73.98 | General |
| Category: ONCOLOGY | ||||||
| 07/21/2022 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Food and Beverage | In-kind items and services | $82.70 | General |
| Category: ONCOLOGY | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $900.00 | Research |
| Study: A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 04/30/2021 | Eli Lilly and Company | — | — | In-kind items and services | $325.00 | Research |
| Study: A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $303.90 | Research |
| Study: A PHASE IB, OPEN-LABEL STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY IN COMBINATION WITH TRASTUZUMAB EMTANSINE OR WITH TRASTUZUMAB AND PERTUZUMAB WITH AND WITHOUT DOCETAXEL IN PATIENTS WITH HER2-POSITIVE BREAST CANCER AND ATEZOLIZUMAB WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE IN HER2-NEGATIVE BREAST CANCER • Category: BioOncology | ||||||
| 09/24/2020 | Eli Lilly and Company | — | — | In-kind items and services | $300.00 | Research |
| Study: A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | ||||||
| 12/31/2019 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,322.96 | General |
| Category: BioOncology | ||||||
| 09/30/2019 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $532.00 | General |
| Category: BioOncology | ||||||
| 04/23/2019 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $27.34 | General |
| Category: ONCOLOGY | ||||||
| 02/27/2019 | Helsinn Therapeutics (U.S.), Inc. | AKYNZEO (Drug) | Education | In-kind items and services | $14.96 | General |
| 02/18/2019 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $11.96 | General |
| Category: ONCOLOGY | ||||||
| 01/22/2019 | Eli Lilly and Company | — | — | Cash or cash equivalent | $5,145.00 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | ||||||
| 01/10/2019 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $40.91 | General |
| 10/25/2018 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $92.67 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2018 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $3.57 | General |
| 12/12/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | AFINITOR (Drug) | — | In-kind items and services | $764.00 | Research |
| Study: RESEARCH RELATED PUBLICATION SUPPORT • Category: ONCOLOGY | ||||||
| 12/07/2017 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $50.73 | General |
| 06/04/2017 | EMD Serono Research & Development Institute | — | Food and Beverage | Cash or cash equivalent | $88.19 | General |
| 06/03/2017 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $111.06 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $5,145 | 1 |
| A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $1,525 | 3 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $764.00 | 1 |
| A PHASE IB, OPEN-LABEL STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY IN COMBINATION WITH TRASTUZUMAB EMTANSINE OR WITH TRASTUZUMAB AND PERTUZUMAB WITH AND WITHOUT DOCETAXEL IN PATIENTS WITH HER2-POSITIVE BREAST CANCER AND ATEZOLIZUMAB WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE IN HER2-NEGATIVE BREAST CANCER | F. Hoffmann-La Roche AG | $303.90 | 1 |
| A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+ HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $300.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 82 | 132 | $28,302 | $11,666 |
| 2022 | 3 | 65 | 134 | $37,667 | $11,790 |
| 2021 | 2 | 43 | 79 | $16,858 | $7,411 |
| 2020 | 2 | 36 | 88 | $27,898 | $7,223 |
Total Patients
226
Total Services
433
Medicare Billing
$38,090
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 43 | 69 | $16,836 | $7,204 | 42.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 39 | 63 | $11,466 | $4,462 | 38.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 30 | 54 | $13,492 | $5,691 | 42.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 16 | 43 | $16,985 | $3,459 | 20.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 19 | 37 | $7,190 | $2,639 | 36.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 22 | 40 | $9,760 | $4,567 | 46.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 21 | 39 | $7,098 | $2,845 | 40.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 13 | 51 | $18,870 | $4,322 | 22.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 23 | 37 | $9,028 | $2,900 | 32.1% |
About Dr. Carla Falkson, MD
Dr. Carla Falkson, MD is a Hematology & Oncology healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1538103122.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Carla Falkson, MD has received a total of $10,680 in payments from pharmaceutical and medical device companies, with $23.93 received in 2024. These payments were reported across 25 transactions from 10 companies. The most common payment nature is "" ($8,038).
As a Medicare-enrolled provider, Falkson has provided services to 226 Medicare beneficiaries, totaling 433 services with total Medicare billing of $38,090. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Rochester, NY
- Active Since 06/15/2006
- Last Updated 06/30/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1538103122
Products in Payments
- TECENTRIQ (Biological) $2,159
- AFINITOR (Drug) $764.00
- KISQALI (Drug) $231.07
- ENHERTU (Drug) $156.68
- Trodelvy (Drug) $23.93
- BRUKINSA (Drug) $19.28
- AKYNZEO (Drug) $14.96
- IBRANCE (Drug) $11.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Rochester
Dr. Alex Spyropoulos, Md, MD
Hematology & Oncology — Payments: $750,882
Hematology & Oncology $750,882
Shaji Kumar, M.d, M.D
Hematology & Oncology — Payments: $722,278
Hematology & Oncology $722,278
David Dingli, M.d, M.D
Hematology & Oncology — Payments: $505,158
Hematology & Oncology $505,158
Amit Mahipal
Hematology & Oncology — Payments: $474,204
Hematology & Oncology $474,204
Yi Lin, M.d, M.D
Hematology & Oncology — Payments: $333,310
Hematology & Oncology $333,310
Grzegorz Nowakowski, M.d, M.D
Hematology & Oncology — Payments: $254,028
Hematology & Oncology $254,028